Why did GAAP EPS diverge so much from adjusted EPS this quarter?

GAAP diluted EPS of $2.87 was reduced by a $249.5 million impairment of assets tied to the U.S. Consulting Services business classified as held for sale, plus about $78 million in acquisition-related deal and integration costs and about $125 million in acquisition-related intangibles amortization. These were partly offset by an $86.8 million litigation and opioid-related credit, a $77.6 million LIFO credit, and a $12.2 million antitrust settlement gain. Adjusted EPS of $4.08 excludes these items.

What does the OneOncology acquisition mean for Cencora's guidance and segments?

The OneOncology acquisition is a key driver of the raised adjusted operating income guidance. Its results will be consolidated within U.S. Healthcare Solutions, which management expects to grow 14%-16% in adjusted operating income in fiscal 2026. The company said the deal cements its specialty MSO footprint in oncology. However, the purchase was funded with debt, which is a reason net interest expense guidance rose sharply.

Is the reaffirmed EPS guidance a sign of weakness given the higher operating income outlook?

Not necessarily. Operating income guidance was raised, but adjusted EPS guidance was held at $17.45-$17.75. The gap is explained by higher net interest expense ($480-$500 million vs. $292 million in fiscal 2025) from the acquisition financing, along with a slightly higher share count of 195.5 million. Investors should evaluate how much of the operating income gain flows through to per-share earnings after these costs.

What is driving the weak operating cash flow and lower cash balance?

The quarter's operating cash outflow of $2.3 billion was driven mainly by a $3.5 billion inventory build and a $0.8 billion increase in receivables, partly offset by a $1.3 billion increase in accounts payable. Cash fell to $1.75 billion from $4.36 billion at fiscal year-end. Management's adjusted free cash flow guidance for the full year is about $3.0 billion, so this quarter's cash profile is seasonal and timing-related rather than a change in the annual outlook.

What is the status of the Other segment and its strategic review?

Other includes MWI Animal Health, Profarma, U.S. Consulting Services, and certain PharmaLex components, and the company is exploring strategic alternatives for these businesses. The quarter included a $249.5 million impairment tied to U.S. Consulting Services held for sale, and Other's adjusted operating income fell 6.1% to $91.4 million. Investors should watch for further divestiture or impairment announcements as the review progresses.

COR 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed February 4, 2026. Cited figures are marked; the original filing is the authoritative source.

Cencora (COR) reported fiscal Q1 2026 (quarter ended December 31, 2025) with revenue of $85.9 billion^a, up 5.5% year-over-year, driven by 5.0% growth in U.S. Healthcare Solutions and 9.6% growth in International Healthcare Solutions.

GAAP diluted EPS was $2.87^b, up 14.8%, while adjusted diluted EPS was $4.08, up 9.4%. GAAP results were weighed down by a $249.5 million impairment tied to the U.S. Consulting Services business held for sale, partly offset by an $86.8 million litigation and opioid-related credit. Adjusted operating income rose 11.9% to $1.06 billion, and U.S. Healthcare Solutions segment operating income grew 21.0%, supported by the January 2025 Retina Consultants of America acquisition.

Management raised its fiscal 2026 adjusted operating income growth guidance to 11.5%-13.5% from 8%-10%, reflecting the completed acquisition of the majority stake in OneOncology for roughly $4.6 billion^c in cash on February 2, 2026, funded with new debt. The adjusted diluted EPS guidance was reaffirmed at $17.45-$17.75. Net interest expense guidance of $480-$500 million is well above the $292 million reported in fiscal 2025, reflecting higher borrowing costs, and the cash flow picture for the quarter was seasonally weak, with operating cash outflow of $2.3 billion driven by inventory build.

Investors should weigh the strong underlying earnings growth and the OneOncology expansion in specialty oncology against higher leverage, rising interest costs, the ongoing strategic review of Other businesses, and a sharp decline in cash balances. The board also declared a quarterly dividend of $0.60^d per share, payable March 2, 2026.

02—Key points

Key Highlights

Revenue rose 5.5% to $85.9 billion, with U.S. Healthcare Solutions up 5.0% and International Healthcare Solutions up 9.6%.
GAAP diluted EPS was $2.87 (up 14.8%), while adjusted diluted EPS was $4.08 (up 9.4%); GAAP results include a $249.5 million impairment on U.S. Consulting Services held for sale.
Adjusted operating income rose 11.9% to $1.06 billion; FY2026 adjusted operating income growth guidance was raised to 11.5%-13.5% from 8%-10%.
Adjusted diluted EPS guidance was reaffirmed at $17.45-$17.75, implying roughly 9%-11% growth over the $16.00 fiscal 2025 actual.
Acquired the majority of the remaining OneOncology equity for about $4.6 billion in cash on February 2, 2026, funded with new debt; results will be consolidated in U.S. Healthcare Solutions.
Net interest expense rose to $72.4 million in the quarter from $27.9 million, and FY2026 net interest expense guidance is $480-$500 million versus $292 million in FY2025.
Cash and equivalents fell to $1.75 billion from $4.36 billion at September 30, 2025, amid a $2.3 billion operating cash outflow driven by a $3.5 billion inventory build; the board declared a $0.60 quarterly dividend.

03—Questions

Frequently Asked Questions

Why did GAAP EPS diverge so much from adjusted EPS this quarter?
GAAP diluted EPS of $2.87 was reduced by a $249.5 million impairment of assets tied to the U.S. Consulting Services business classified as held for sale, plus about $78 million in acquisition-related deal and integration costs and about $125 million in acquisition-related intangibles amortization. These were partly offset by an $86.8 million litigation and opioid-related credit, a $77.6 million LIFO credit, and a $12.2 million antitrust settlement gain. Adjusted EPS of $4.08 excludes these items.
What does the OneOncology acquisition mean for Cencora's guidance and segments?
The OneOncology acquisition is a key driver of the raised adjusted operating income guidance. Its results will be consolidated within U.S. Healthcare Solutions, which management expects to grow 14%-16% in adjusted operating income in fiscal 2026. The company said the deal cements its specialty MSO footprint in oncology. However, the purchase was funded with debt, which is a reason net interest expense guidance rose sharply.
Is the reaffirmed EPS guidance a sign of weakness given the higher operating income outlook?
Not necessarily. Operating income guidance was raised, but adjusted EPS guidance was held at $17.45-$17.75. The gap is explained by higher net interest expense ($480-$500 million vs. $292 million in fiscal 2025) from the acquisition financing, along with a slightly higher share count of 195.5 million. Investors should evaluate how much of the operating income gain flows through to per-share earnings after these costs.
What is driving the weak operating cash flow and lower cash balance?
The quarter's operating cash outflow of $2.3 billion was driven mainly by a $3.5 billion inventory build and a $0.8 billion increase in receivables, partly offset by a $1.3 billion increase in accounts payable. Cash fell to $1.75 billion from $4.36 billion at fiscal year-end. Management's adjusted free cash flow guidance for the full year is about $3.0 billion, so this quarter's cash profile is seasonal and timing-related rather than a change in the annual outlook.
What is the status of the Other segment and its strategic review?
Other includes MWI Animal Health, Profarma, U.S. Consulting Services, and certain PharmaLex components, and the company is exploring strategic alternatives for these businesses. The quarter included a $249.5 million impairment tied to U.S. Consulting Services held for sale, and Other's adjusted operating income fell 6.1% to $91.4 million. Investors should watch for further divestiture or impairment announcements as the review progresses.

04—Continue

← View all 8-K filings